By ACTG
LOS ANGELES, March 08, 2025 (GLOBE NEWSWIRE) — ACTG, a global clinical trials network focused on HIV and other infectious diseases, today presented data demonstrating that switching to an integrase inhibitor-based antiretroviral regimen increased the risk of weight gain and cardiometabolic complications over the next five years compared to remaining on a regimen without an integrase inhibitor. They did not find an increased risk of major adverse cardiovascular events (MACE), such as heart attacks or strokes. These results from the REPRIEVE (The Randomized Trial to Prevent Vascular Events in HIV) study were shared as the late breaking poster presentation, “Risk of Obesity, Cardiometabolic Disease and MACE after Switch to an Integrase Inhibitor in REPRIEVE” at the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco, California.
Read the full press release here.
